Brief: Stoke Therapeutics Announces Completion Of Enrollment Of 162 Patients Into The Phase 3 Emperor Study Of Zorevunersen, An Investigational Medicine For The Treatment Of Dravet Syndrome
30/06/2026 13:39
BRIEF-Stoke Therapeutics Announces Completion Of Enrollment Of 162 Patients Into The Phase 3 Emperor Study Of Zorevunersen, An Investigational Medicine For The Treatment Of Dravet Syndrome June 30 (Reuters) - Stoke Therapeutics Inc STOK.O:
STOKE THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF 162 PATIENTS INTO THE PHASE 3 EMPEROR STUDY OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME
STOKE THERAPEUTICS - PLANS TO INITIATE ROLLING U.S. NDA SUBMISSION TO FDA IN Q1 2027
STOKE THERAPEUTICS - PHASE 3 DATA READOUT ANTICIPATED IN Q3 2027, TO COMPLETE NDA SUBMISSION IN H2 2027
STOKE THERAPEUTICS - NO PATIENTS HAVE DISCONTINUED TREATMENT IN PHASE 3 EMPEROR STUDY
Source text: ID:nBw5pdyvXa
Further company coverage: STOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics